Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Future Outlook: Treating Advanced Melanoma

November 30th 2018

Emerging Triplet Regimens in Advanced Melanoma

November 30th 2018

Emerging Combination Therapies in Advanced Melanoma

November 30th 2018

Intralesional Therapy in Metastatic Melanoma

November 30th 2018

Managing Brain Mets in Melanoma

November 30th 2018

BRAF/MEK Inhibitors in Metastatic Melanoma

November 30th 2018

Combination Ipilimumab/Nivolumab in Metastatic Melanoma

November 30th 2018

Anti-PD-1 Therapy in Metastatic Melanoma

November 30th 2018

Role of Neoadjuvant Therapy for Melanoma

November 30th 2018

Adjuvant Therapy in Melanoma: Targeted vs Immuno-Oncology

November 30th 2018

Anti-PD-1 Adjuvant Therapy in Melanoma

November 30th 2018

Adjuvant Therapy in Melanoma: COMBI-AD Trial

November 30th 2018

Molecular Testing for Stage III Melanoma

November 30th 2018

Completion Lymph Node Dissection in Melanoma

November 30th 2018

Management of Locally Advanced Melanoma

November 30th 2018

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

November 30th 2018

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.

Triplet Therapy With Novel PD-1 Inhibitor Holds Promise in Melanoma

November 28th 2018

The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma.

Dr. Tawbi on Checkpoint Inhibition in Melanoma

November 26th 2018

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the promise of checkpoint inhibition in the treatment of melanoma.

Dr. Weber on Duration of Checkpoint Inhibitor Therapy in Melanoma

November 15th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.

Kirkwood Helped Chart Course of Adjuvant Immunotherapy in Melanoma

November 12th 2018

In the 44 years since John M. Kirkwood, MD began his career, he has seen melanoma become a growing field of research.